MK-9999-02A
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers
Recruiting
Trial purpose
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:
* About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it
* How many people have the cancer respond (get smaller or go away) to treatment
NATIONAL TRIAL REFERENCE NUMBER
NCT06428409
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Biliary Tract Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Age Range
18+
Sex
Male/Female
Study Details
About the trial
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.